HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape - PubMed
6 hours ago
- #HER2
- #NSCLC
- #targeted therapy
- HER2 alterations in NSCLC include protein overexpression, gene amplification, and activating mutations.
- Targeted therapies like trastuzumab deruxtecan (FDA-approved for HER2-mutant NSCLC), TKIs (zongertinib, sevabertinib) show efficacy and intracranial penetration.
- Review covers molecular landscape, clinical phenotypes of HER2-altered NSCLC, and ongoing clinical trial data.
- Future research needed on resistance mechanisms and optimal treatment sequencing/combinatorial strategies.